publication date: Mar. 10, 2017

Drugs and Targets NICE recommends Vectibix for previously untreated metastatic colorectal cancer

The National Institute for Health and Care Excellence issued a Final Appraisal Determination recommending panitumumab as an option for patients with previously untreated, RAS wild-type metastatic colorectal cancer in adults in combination with the FOLFOX or FOLFIRI chemotherapy regimens.

NICE evaluated the clinical and cost-effectiveness of panitumumab and cetuximab in the Multiple Technology Appraisal and concluded that both are cost-effective use of NHS resources.

The FAD recommends panitumumab within its marketing authorization and on the basis of the discounts agreed in the patient access scheme with NICE.

Panitumumab is the only fully-human monoclonal anti-epidermal growth factor receptor antibody authorized for the treatment of wild-type RAS metastatic colorectal cancer.

The NICE FAD for panitumumab is published as a Multiple Technology Appraisal, which also includes cetuximab. Both treatments were recommended within their marketing authorization, provided they meet the discounts agreed in their patient access schemes. The FAD is not NICE’s Final Guidance for panitumumab – it is expected to become Final Guidance to the NHS in England and Wales in April 2017.

 

EnGeneIC receives Orphan designation for its technology in glioblastoma multiforme

EnGeneIC Ltd., a clinical stage biopharmaceutical company focused on developing its proprietary EDV … Continue reading NICE recommends Vectibix for previously untreated metastatic colorectal cancer

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.